ReviewJapanese journal of radiology2016
Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.
Review in Japanese journal of radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Clinical Significance of Bone Metastases in Pleural Mesothelioma.Thoracic cancer · 2025Article
- The Prognostic Value ofJournal of clinical medicine · 2021Review
- Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2021Article
- Deep learning with deep convolutional neural network using FDG-PET/CT for malignant pleural mesothelioma diagnosis.Oncotarget · 2021Article
- A Case of Pulmonary Embolism with Sarcomatoid Malignant Pleural Mesothelioma with Long-Term Pleural Effusion.OncoTargets and therapy · 2021Article
- Imaging for Response Assessment in Cancer Clinical Trials.Seminars in nuclear medicine · 2020Article
- Article
- Clinical staging of malignant pleural mesothelioma: current perspectives.Lung Cancer (Auckland, N.Z.) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Positron emission tomography/computed tomography (PET/CT) integrated with 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) has emerged as a powerful tool for combined metabolic and anatomic evaluations in clinical oncologic imaging. This review discusses the utility of (18)F-FDG PET/CT as a tool to manage patients with malignant pleural mesothelioma. We discuss different stages of patient management in malignant pleural mesothelioma, including diagnosis, initial staging, therapy planning, early treatment response assessment, re-staging, and prognosis.
Indexed as
Identifiers
27222020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.